California State Teachers Retirement System Sells 595 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

California State Teachers Retirement System lowered its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,369 shares of the company’s stock after selling 595 shares during the quarter. California State Teachers Retirement System owned about 0.08% of Amphastar Pharmaceuticals worth $1,350,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its position in Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares in the last quarter. Parkside Financial Bank & Trust grew its position in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after acquiring an additional 871 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Amphastar Pharmaceuticals in the fourth quarter worth $38,000. Tower Research Capital LLC TRC grew its position in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after acquiring an additional 348 shares in the last quarter. Finally, Huntington National Bank grew its position in Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company’s stock worth $50,000 after acquiring an additional 361 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $26.62 on Tuesday. The company has a 50-day simple moving average of $24.62 and a two-hundred day simple moving average of $31.28. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 8.87, a PEG ratio of 2.19 and a beta of 0.77.

Analysts Set New Price Targets

AMPH has been the subject of several research reports. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Piper Sandler cut their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Finally, Wells Fargo & Company cut their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.